UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
54561,Clearstream,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213385/28124/en/United-Kingdom-Colocation-Data-Center-Portfolio-Report-2025-2029-Detailed-Analysis-of-243-Existing-Data-Centers-66-Upcoming-Data-Centers-and-131-Major-Operators-Investors.html,United Kingdom Colocation Data Center Portfolio Report 2025-2029: Detailed Analysis of 243 Existing Data Centers  66 Upcoming Data Centers  and 131 Major Operators/Investors,Introducing a comprehensive UK data center market portfolio analysis in Excel format  featuring in-depth coverage of colocation data centers. This database provides a detailed examination of 243 existing centers and 66 upcoming facilities across key locations…,"Dublin  Jan. 06  2026 (GLOBE NEWSWIRE) -- The ""United Kingdom Existing & Upcoming Data Center Portfolio"" report has been added to ResearchAndMarkets.com's offering.UK hosts around 240+ existing data centers  with Cities like London  Slough and Newport having a strong presence in the region. London dominates the upcoming data center market with more than 1.6 GW led by Digital Reef  Equnix  Ada Infrastructure and Tritax Big Box.There is growing demand from cloud and tech companies  especially in London  Manchester  and Birmingham.VIRTUS Data Centres  Equinix  Digital Realty  Vantage Data Centres and Ark Data Centres rank among the leading data center operators by capacity across UK.KEY MARKET HIGHLIGHTS:This database (Excel) product covers the UK data center market portfolio analysis  which provides the following information on colocation data centers:Detailed Analysis of 243 existing data centersDetailed Analysis of 66 upcoming data centersLocations covered: Bedfordshire  Berkshire  Bristol  Buckinghamshire  Cambridge  Chertsey  Cheshire  Corsham  Derbyshire  Dorset  Dunkirk  Essex  Farnborough  Gloucestershire  Greater London  Greater Manchester  Hampshire  Harlow  Hayes  Hertfordshire  Iver Heath  Kent  Killingholme  Leicestershire  London  Manchester  Merseyside  Middlesbrough  North Yorkshire  Northamptonshire  Nottinghamshire  Scotland  Slough  South Yorkshire  Surrey  Tyne & Wear  Wales  Warwickshire  West Midlands  West Sussex  West Yorkshire  Wiltshire.Existing white-floor space (square feet)Upcoming white-floor space (square feet)Current IT load capacity (2025)Future capacity additions (2025-2029)Retail Colocation Pricing Quarter Rack (1/4) Half Rack Cabinets (1/2) Full Rack Cabinet (42U/45U/47U/etc.)Wholesale colocation (per kW) pricingEXISTING DATA CENTERS (243 FACILITIES)Market SnapshotLocation (Region/Country/City)Facility AddressOperator/Owner NameData Center Name i.e.  (London II or Glasgow Data Center)Core & Shell Area (White-Floor Area)Core & Shell Power Capacity (IT Load Capacity)Rack CapacityYear of OperationsDesign Standards (Tier I - IV)Power/Cooling RedundancyUPCOMING DATA CENTERS (66 FACILITIES)Investment SnapshotLocation (Region/Country/City)Investor NameArea (White-Floor Area)Power Capacity (IT Load Capacity)Investment ($ Million)Electrical Infrastructure Investment ($ Million)Mechanical Infrastructure Investment ($ Million)General Construction Services Investment ($ Million)Announcement YearProject Status (Opened/Under Construction/Announced & Planned)Active or Expected Year of OpeningTARGET AUDIENCEData center Real Estate Investment Trusts (REIT)Data center Construction ContractorsData center Infrastructure ProvidersNew EntrantsConsultants/Consultancies/Advisory FirmsCorporate and Governments AgenciesKey Topics Covered:1. About the Database2. Scope & Assumptions3. Definitions4. Snapshot: Existing & Upcoming Data Center Facility5. Existing Data Center Database6. Upcoming Data Center Facility7. Existing vs. Upcoming Capacity (Infographics)8. Colocation PricingMajor Operators/investors Covered in This United Kingdom Data Center Market4D Data CentresAccess Managed Services (OOSHA)Ada InfrastructureAI PathfinderAIMESAiOnXANS Group (UKFast)ApaturaAptumAQL Data CenterArk Data CentresArrow Business CommunicationsAsanti (Daisy Group)ASK4AtlasEdgeBlue BoxbrightsolidCainealCapitaLandCarbon3.aiCastleforge and Galaxy DCCatella (Trinity DC)CCS LeedsCentersquare (Cyxtera Technologies)CentrilogicChina Mobile International (CMI)Clearstream TechnologyCloud Innovation LimitedCloudHQCogent CommunicationsColt Data Centre ServicesColumbia Threadneedle (Node4)CorscaleCustodian Data CentresCyrusOneDaisy Corporate ServicesDante FS GroupDataBankDatacentreplusDATANET.CO.UKDataVitaDatumDatum Datacentres (Teledata)DDCL Tutis PointDeep GreenDigital RealtyDigital ReefDigital Space (Timico)DLD (Salford) LtdEchelon Data CentersEdgeCoreEID LLPElasticity LimitedElite UK REIT Management Pte. LtdElsham Tech Park LtdEpsilon TelecommunicationsEquinixFujitsuFulcrum Data SystemsGlobal SwitchGlobal Technical Realty (GTR)Gravity Edge (Previously Lincoln Rackhouse)Green Mountain (Infinity SDC)GreenWeaver AI Ltd (Spode Works Regeneration Ltd)Gridjet Data CentresGTP 3 Data CenterGTT (I Squared)Humber Tech ParkIndectronIntercity TechnologyIOMARTIonos (Fasthosts)IP HouseIron MountainItilityITPSKao DataKeppel Data CentresKwere IILatos Data CenterLDeXLink Park HeathrowLumen TechnologiesLunar DigitalMedia Stream AI (MSAI)MigSolvNetwise HostingnLightenNorthtree Investment ManagementNorwich Research ParkNscaleNTT DATANTT Global Data CentersOrigin Power Services and Woodlands Investment Management LimitedPATRIZIAPulsantPulsant (SCC)PureDCQTSQuickHostRackspace TechnologyRedwire DCSafe Hosts InternetSafenames Data CentreSalt Ayre Leisure CentreSegroServerChoiceServerfarmServerHouseService Express (Blue Chip)Shelborn Drummond LtdSilverEdge DCSix DegreesStellanor Datacenters Group Limited (Redcentric)Stellium DatacentersSUB1Sungard Availability ServicesTelehouseTelstraThe Bunker (Cyberfort Group)THG HostingThriveTritax Big BoxValore GroupVantage Data Centers (Next Generation Data)Verne Global (Volta Data Centres)VIRTUS Data Centres (ST Telemedia Global Data Centres)Wildcard NetworksWilton InternationalWRN BroadcastYondrFor more information about this report visit https://www.researchandmarkets.com/r/g2vjc1About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets  key industries  the top companies  new products and the latest trends.",neutral,0.0,1.0,0.0,positive,0.61,0.38,0.01,True,English,"['United Kingdom Colocation Data Center Portfolio Report', '243 Existing Data Centers', '66 Upcoming Data Centers', 'Detailed Analysis', '131 Major Operators/Investors', 'Elasticity Limited Elite UK REIT Management Pte. Ltd', 'Facility Address Operator/Owner Name Data Center Name', 'Netwise Hosting nLighten Northtree Investment Management', 'Safenames Data Centre Salt Ayre Leisur', 'Data center Real Estate Investment Trusts', '4D Data Centres Access Managed Services', 'AQL Data Center Ark Data Centres', 'UK data center market portfolio analysis', 'AtlasEdge Blue Box brightsolid Caineal', 'Clearstream Technology Cloud Innovation Limited', 'United Kingdom Data Center Market', 'Woodlands Investment Management Limited', 'Retail Colocation Pricing Quarter Rack', 'Colt Data Centre Services', 'Upcoming Data Center Portfolio', 'Upcoming Data Center Facility', 'leading data center operators', 'DataVita Datum Datum Datacentres', 'Spode Works Regeneration Ltd', 'upcoming data center market', 'Data center Construction Contractors', 'LDeX Link Park Heathrow', 'Data center Infrastructure Providers', 'General Construction Services Investment', 'Announcement Year Project Status', 'Arrow Business Communications Asanti', 'Elsham Tech Park Ltd', '240+ existing data centers', 'Current IT load capacity', 'Lumen Technologies Lunar Digital', 'NTT Global Data Centers', 'Existing Data Center Database', 'Glasgow Data Center', 'GTP 3 Data Center', 'Latos Data Center', 'Investor Name Area', 'United Kingdom Existing', 'VIRTUS Data Centres', 'Vantage Data Centres', 'Custodian Data Centres', 'Gridjet Data Centres', 'Keppel Data Centres', '66 upcoming data centers', 'colocation data centers', 'Echelon Data Centers', 'Tritax Big Box', '243 existing data centers', 'Fulcrum Data Systems', 'DATANET.CO.UK', 'KEY MARKET HIGHLIGHTS', 'Origin Power Services', 'Electrical Infrastructure Investment', 'Mechanical Infrastructure Investment', 'Market Snapshot Location', 'Half Rack Cabinets', 'Full Rack Cabinet', 'GreenWeaver AI Ltd', 'Humber Tech Park', 'Norwich Research Park', 'QuickHost Rackspace Technology', 'Rack Capacity Year', 'Investment Snapshot Location', 'Operations Design Standards', 'New Entrants Consultants', 'CCS Leeds Centersquare', 'China Mobile International', 'DDCL Tutis Point', 'PATRIZIA Pulsant Pulsant', 'Safe Hosts Internet', 'Future capacity additions', 'Upcoming white-floor space', 'Daisy Corporate Services', 'Media Stream AI', 'Galaxy DC Catella', 'Dante FS Group', 'Global Technical Realty', 'Existing white-floor space', 'Shell Power Capacity', 'NTT DATA', 'Upcoming Capacity', 'Kao Data', '8. Colocation Pricing', 'Detailed Analysis', 'Under Construction', 'Intercity Technology', 'tech companies', 'Wholesale colocation', 'Expected Year', 'Cyxtera Technologies', 'Cogent Communications', 'Digital Space', 'Global Switch', 'Daisy Group', 'Ada Infrastructure', 'Shell Area', 'White-Floor Area', 'Digital Realty', 'Key Topics', 'AI Pathfinder', 'Carbon3.ai', 'Digital Reef', 'ANS Group', 'Trinity DC', 'Redwire DC', 'GLOBE NEWSWIRE', 'strong presence', 'growing demand', 'following information', 'Iver Heath', 'North Yorkshire', 'South Yorkshire', 'West Midlands', 'West Sussex', 'West Yorkshire', 'square feet', 'Tier I', 'Power/Cooling Redundancy', 'TARGET AUDIENCE', 'Advisory Firms', 'Governments Agencies', 'Columbia Threadneedle', 'Deep Green', 'EID LLP', 'Epsilon Telecommunications', 'Gravity Edge', 'Lincoln Rackhouse', 'Green Mountain', 'IOMART Ionos', 'IP House', 'Iron Mountain', 'Kwere II', 'Greater London', 'Greater Manchester', 'London II', '4. Snapshot', 'Dublin', 'The', 'report', 'ResearchAndMarkets.', 'offering', 'Cities', 'Slough', 'Newport', 'region', '1.6 GW', 'Equnix', 'Birmingham', 'Equinix', 'Locations', 'Bedfordshire', 'Berkshire', 'Bristol', 'Buckinghamshire', 'Cambridge', 'Chertsey', 'Cheshire', 'Corsham', 'Derbyshire', 'Dorset', 'Dunkirk', 'Essex', 'Farnborough', 'Gloucestershire', 'Hampshire', 'Harlow', 'Hayes', 'Hertfordshire', 'Kent', 'Killingholme', 'Leicestershire', 'Merseyside', 'Middlesbrough', 'Northamptonshire', 'Nottinghamshire', 'Scotland', 'Surrey', 'Tyne', 'Wear', 'Wales', 'Warwickshire', 'Wiltshire', 'Country/City', 'Core', '66 FACILITIES', 'Active', 'Opening', 'Consultancies', 'Scope', 'Assumptions', 'Definitions', 'Infographics', 'investors', 'OOSHA', 'AIMES', 'AiOnX', 'UKFast', 'Apatura', 'Aptum', 'ASK4', 'CapitaLand', 'Castleforge', 'Centrilogic', 'CMI', 'CloudHQ', 'Corscale', 'CyrusOne', 'DataBank', 'Datacentreplus', 'Teledata', 'Timico', 'DLD', 'Salford', 'Fujitsu', 'GTR', 'Infinity SDC', 'GTT', 'Indectron', 'Fasthosts', 'Itility', 'ITPS', 'MSAI', 'MigSolv', 'Nscale', 'SCC', 'PureDC', 'QTS', '5.']",2026-01-06,2026-01-07,globenewswire.com
54562,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213309/0/en/argenx-to-Present-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html,argenx to Present at 44th Annual J.P. Morgan Healthcare Conference,January 6  2026Amsterdam  the Netherlands – argenx (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  today announced that Tim Van Hauwermeiren  Chief Executive Officer …,January 6  2026Amsterdam  the Netherlands – argenx (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  today announced that Tim Van Hauwermeiren  Chief Executive Officer  will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday  January 12  2026 at 8:15 a.m. PT.A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP)  argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information  visit www.argenx.com and follow us on LinkedIn  Instagram  Facebook  and YouTube.For further information  please contact:Media:Ben Petokbpetok@argenx.comInvestors:Alexandra Royaroy@argenx.com,neutral,0.01,0.99,0.0,neutral,0.02,0.95,0.03,True,English,"['44th Annual J.P. Morgan Healthcare Conference', 'argenx', '44th Annual J.P. Morgan Healthcare Conference', 'several earlier stage experimental medicines', 'multiple serious autoimmune diseases', 'novel antibody-based medicines', 'severe autoimmune diseases', 'Tim Van Hauwermeiren', 'Chief Executive Officer', 'leading academic researchers', 'neonatal Fc receptor', 'Ben Petok bpetok', 'Alexandra Roy aroy', 'global immunology company', 'Immunology Innovation Program', 'immunology breakthroughs', 'world-class portfolio', 'FcRn) blocker', 'broad potential', 'therapeutic franchises', 'live webcast', 'Investors section', 'argenx website', 'January', 'Amsterdam', 'Netherlands', 'Euronext', 'Nasdaq', 'ARGX', 'lives', 'people', 'Monday', '8:15 a', 'presentation', 'replay', '30 days', 'IIP', 'first', 'information', 'LinkedIn', 'Instagram', 'Facebook', 'YouTube', 'Media']",2026-01-06,2026-01-07,globenewswire.com
54563,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213999/0/en/REXEL-Change-in-Rexel-s-financial-agenda.html,REXEL: Change in Rexel’s financial agenda,Change in Rexel’s financial agenda     Initially planned for February 12  2026  the publication of Rexel's full-year 2025 results and the conference call...,Change in Rexel’s financial agendaInitially planned for February 12  2026  the publication of Rexel's full-year 2025 results and the conference call have been moved forward to Wednesday  February 11  2026 after market close.This change is due to numerous companies’ results in the Capital Goods sector scheduled for February 12. Further information related to time and connection details will be communicated in the coming weeks.ABOUT REXEL GROUPRexel  worldwide expert in the multichannel professional distribution of products and services for the energy world  addresses three main markets: residential  non-residential  and industrial. The Group supports its residential  non-residential  and industrial customers by providing a tailored and scalable range of products and services in energy management for construction  renovation  production  and maintenance. Rexel operates through a network of more than 1 875 branches in 17 countries  with more than 26 550 employees. The Group’s sales were €19.3 billion in 2024.Rexel is listed on the Eurolist market of Euronext Paris (compartment A  ticker RXL  ISIN code FR0010451203). It is included in the following indices: MSCI World  CAC Next 20  SBF 120  CAC Large 60  CAC SBT 1.5 NR  CAC AllTrade  CAC AllShares  FTSE EuroMid  and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good  Dow Jones Sustainability Index Europe  Euronext Sustainable Europe 120 and S&P Global Sustainability Yearbook 2025  in recognition of its performance in terms of Corporate Social Responsibility (CSR).For more information  visit www.rexel.com/en.CONTACTSFINANCIAL ANALYSTS/INVESTORSLudovic DEBAILLEUX +33 1 42 85 76 12 ludovic.debailleux@rexel.comPRESSEBrunswick: Laurence FROST +33 6 31 65 57 06 lfrost@brunswickgroup.comAttachment,neutral,0.01,0.98,0.01,neutral,0.02,0.97,0.01,True,English,"['financial agenda', 'REXEL', 'Change', 'S&P Global Sustainability Yearbook', 'Dow Jones Sustainability Index Europe', 'Euronext Sustainable Europe', 'Capital Goods sector', 'multichannel professional distribution', 'three main markets', 'Corporate Social Responsibility', 'numerous companies’ results', 'following SRI indices', 'following indices', 'full-year 2025 results', 'Euronext Paris', 'financial agenda', 'conference call', 'market close', 'connection details', 'coming weeks', 'energy world', 'The Group', 'scalable range', 'energy management', 'Eurolist market', 'compartment A', 'ticker RXL', 'ISIN code', 'MSCI World', 'CAC Next', 'CAC Large', 'CAC SBT', 'CAC AllTrade', 'CAC AllShares', 'FTSE EuroMid', 'FINANCIAL ANALYSTS/INVESTORS', 'Laurence FROST', 'Further information', 'industrial customers', 'REXEL GROUP', 'Ludovic DEBAILLEUX', 'Change', 'February', 'publication', 'Wednesday', 'time', 'expert', 'products', 'services', 'residential', 'tailored', 'construction', 'renovation', 'production', 'maintenance', 'network', '1,875 branches', '17 countries', '26,550 employees', 'sales', 'SBF', 'NR', 'STOXX600', 'FTSE4Good', 'recognition', 'performance', 'terms', 'CSR', 'CONTACTS', 'PRESSE', 'Brunswick', 'lfrost', 'Attachment']",2026-01-06,2026-01-07,globenewswire.com
54564,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213994/0/en/GENFIT-Favorable-Phase-1-Safety-Profile-and-Strong-Anti-Inflammatory-Activity-for-ACLF-Lead-Asset-G1090N.html,GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N,Lille (France)  Cambridge (Massachusetts  United States)  Zurich (Switzerland)  January 6  2026 - GENFIT (Euronext: GNFT)  a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases  today announced …,"Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile  supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was evidenced through functional ex vivo assays on blood samples from study participants and cirrhotic donors  showing inhibition of pro-inflammatory pathwayFindings provide a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuumLille (France)  Cambridge (Massachusetts  United States)  Zurich (Switzerland)  January 6  2026 - GENFIT (Euronext: GNFT)  a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases  today announced that G1090N – a small molecule and the Company’s lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile  and a strong anti-inflammatory activity in ex-vivo studies.Dr. Jacqueline O’Leary  MD at the UT Southwestern Medical Center  Dallas  TX (USA)  commented: “The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for patients with acute decompensation and for patients with ACLF  a life-threatening condition with no approved therapies and significant unmet medical need. We are eager to see more patient data as the program moves forward  to confirm G1090N’s safety and strengthen the case for its activity in patients with organ failure.”Phase 1The Phase 1  open-label trial assessed the safety  tolerability and pharmacokinetics (PK) of G1090N in healthy volunteers following a Single Ascending Dose administration (SAD) phase  and a Multiple Ascending Dose administration (MAD) phase. 13 healthy volunteers were enrolled in each segment  with a total of 76 participants. G1090N’s safety profile observed in healthy volunteers supports continued evaluation.Ex vivo studiesGENFIT evaluated the modulation of inflammation-related signaling pathways in ex vivo pharmacodynamic and proof-of-efficacy assays:G1090N demonstrated robust biological activity in peripheral blood mononuclear cells (PBMC) assays from healthy volunteers using blood samples from Phase 1 study participants  on LPS-induced IL-6 and TNFα cytokines production  with up to 76% statistically significant inhibition (p<0.0001);The bioactive metabolite of G1090N confirmed its anti-inflammatory potential on ex vivo assays performed on blood collected from cirrhotic donors.These findings indicate that G1090N:Displays strong anti-inflammatory activity at the doses tested in the first-in-human studyEffectively engages its target mechanism of action in circulating immune cellsModulates key pathways driving systemic inflammation  a major contributor to acute decompensated cirrhosis with or without ACLF.Next stepsThese results support further clinical development of G1090N. GENFIT will engage with regulatory authorities  including the U.S. Food and Drug Administration  to determine the best approach for progressing to Phase 2 proof-of-concept in inflammatory conditions such as ACLF where systemic immune dysregulation is a critical driver of disease progression.ENDABOUT GENFITGENFIT is a biopharmaceutical company committed to improving the lives of patients with rare  life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades.Today  GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action  selected to address key pathophysiological pathways. GENFIT also targets other serious diseases  such as cholangiocarcinoma (CCA)  urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio  covering several stages of development  ensures a constant news flow.GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA)  the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1Beyond therapies  GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH  formerly known as NASH for non-alcoholic steatohepatitis).GENFIT  a BCorp™ certified company since 2025  is headquartered in Lille  France and has offices in Paris (France)  Zurich (Switzerland) and Cambridge  MA (USA). The Company is listed on the Euronext regulated market in Paris  Compartment B (Euronext: GNFT). In 2021  Ipsen became one of GENFIT's largest shareholders  acquiring an 8% stake in the Company's capital. www.genfit.comFORWARD LOOKING STATEMENTSThis press release contains certain forward-looking statements with respect to GENFIT  including  but not limited to  statements about the future development of G1090N  including plans to advance into Phase 2 proof-of-concept studies  anticipated regulatory interactions  potential therapeutic benefits in ACLF and related conditions  and the expected progression of GENFIT’s research and development programs. The use of certain words  such as ""believe""  ""potential""  ""expect""  “target”  “may”  “will”  ""should""  ""could""  ""if"" and similar expressions  is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management  these forward-looking statements are subject to numerous known and unknown risks and uncertainties  which could cause actual results to differ materially from those expressed in  or implied or projected by  the forward-looking statements. These risks and uncertainties include  among others  the uncertainties inherent in research and development  including in relation to non-clinical and pre-clinical programs  reproducibility of preclinical results  the translation of animal model data to human biology  in relation to safety of drug candidates  cost of  progression of  and results from  our ongoing and planned clinical trials  patient recruitment  review and approvals by regulatory authorities in the United States  Europe and worldwide  of our drug and diagnostic candidates  pricing  approval and commercial success of elafibranor in the relevant jurisdictions  exchange rate fluctuations  and our continued ability to raise capital to fund our development  as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF  including those listed in Chapter 2 ""Risk Factors and Internal Control"" of the Company's 2024 Universal Registration Document filed on April 29  2025 (no. 25-0331) with the Autorité des marchés financiers (""AMF"")  which is available on GENFIT's website (www.genfit.com) and the AMF's website (bdif.amf-france.org)  and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission (""SEC"")  including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29  2025 and subsequent filings and reports filed with the AMF or SEC  including the Half-Year Business and Financial Report at June 30  2025  or otherwise made public  by the Company. In addition  even if the results  performance  financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements  they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law  the Company does not undertake any obligation to update or revise any forward-looking information or statements  whether as a result of new information  future events or otherwise.CONTACTSGENFIT | InvestorsJean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | jean-christophe.marcoux@genfit.comGENFIT | MediaBruno Arabian – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.frStephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.comGENFIT | 885 Avenue Eugène Avinée  59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com1 Elafibranor is marketed and commercialized  notably in the U.S and Europe  by Ipsen under the trademark Iqirvo® .Attachment",neutral,0.0,1.0,0.0,mixed,0.27,0.35,0.38,True,English,"['Favorable Phase 1 Safety Profile', 'ACLF Lead Asset G1090N', 'Strong Anti-Inflammatory Activity', 'GENFIT', 'Dr. Jacqueline O’Leary', 'UT Southwestern Medical Center', 'Single Ascending Dose administration', 'Multiple Ascending Dose administration', 'significant unmet medical need', 'Healthcare products Regulatory Agency', 'peripheral blood mononuclear cells', 'lead investigational drug candidate', 'functional ex vivo assays', 'rare, life-threatening liver diseases', 'favorable Phase 1 safety profile', 'other serious diseases', 'TNFα cytokines production', 'U.S. Food', 'urea cycle disorders', 'R&D portfolio', 'constant news flow', 'Primary Biliary Cholangitis', 'Chronic Liver Failure', 'liver disease research', 'consistent biological activity', 'inflammation-related signaling pathways', 'robust biological activity', '76% statistically significant inhibition', 'solid scientific heritage', 'advanced pre-commercialization stages', 'European Medicines Agency', 'Metabolic dysfunction-associated steatohepatitis', 'Compelling anti-inflammatory activity', 'strong anti-inflammatory activity', 'Phase 1, open-label trial', 'key pathophysiological pathways', 'Ex vivo studies', 'systemic immune dysregulation', 'acute decompensated cirrhosis', 'BCorp™ certified company', 'investigational drug-candidate G1090N', 'Euronext regulated market', 'Phase 1 study participants', 'Drug Administration', 'immune cells', 'medical needs', 'favorable safety', 'key pathways', 'promising candidate', 'life-threatening condition', 'vivo pharmacodynamic', 'regulatory authorities', 'anti-inflammatory potential', 'organ failure', 'efficacy assays', 'solid foundation', 'systemic inflammation', 'disease progression', 'several stages', 'alcoholic steatohepatitis', 'ex-vivo studies', 'human study', 'blood samples', 'Phase 2 proof', 'SAD) phase', 'MAD) phase', 'tolerability profile', 'clinical evaluation', 'cirrhotic donors', 'pro-inflammatory pathway', 'United States', 'small molecule', 'meaningful step', 'patient data', 'healthy volunteers', 'continued evaluation', 'LPS-induced IL-6', 'bioactive metabolite', 'target mechanism', 'major contributor', 'Next steps', 'best approach', 'inflammatory conditions', 'critical driver', 'rich history', 'two decades', 'associated conditions', 'hepatic encephalopathy', 'therapeutic assets', 'complementary mechanisms', 'organic acidemia', 'high-potential molecules', 'accelerated approval', 'United Kingdom', 'several countries', 'diagnostic franchise', 'Compartment B', 'concept studies', 'biopharmaceutical company', 'acute decompensation', 'Phase 1 results', 'clinical development', 'ACLF continuum', '76 participants', 'G1090N.', 'Findings', 'Lille', 'France', 'Cambridge', 'Massachusetts', 'Zurich', 'Switzerland', 'GENFIT', 'GNFT', 'lives', 'patients', 'MD', 'Dallas', 'TX', 'USA', 'therapies', 'program', 'case', 'pharmacokinetics', 'PK', 'segment', 'total', 'modulation', 'PBMC', 'up', 'doses', 'action', 'pioneer', 'cholangiocarcinoma', 'CCA', 'UCD', 'expertise', 'early', 'Iqirvo®', 'elafibranor', 'FDA', 'EMA', 'MHRA', 'treatment', 'PBC', 'NIS2+®', 'detection', 'MASH', 'NASH', 'offices', 'Paris']",2026-01-06,2026-01-07,globenewswire.com
54565,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213932/0/en/BIC-Disclosure-Of-Trading-In-Own-Shares-For-December-2025.html,BIC: Disclosure Of Trading In Own Shares For December 2025,Disclosure Of Trading In Own Shares For December 2025  Clichy  France – January 06  2026  In compliance with general regulation on share buy-backs  Société...,Disclosure Of Trading In Own Shares For December 2025Clichy  France – January 06  2026In compliance with general regulation on share buy-backs  Société BIC declares below the transactions made on its own shares for December 2025:No transactions for December 2025.ContactsBrice ParisVP Investor Relations+33 6 42 87 54 73brice.paris@bicworld.comInvestor Relationsinvestors.info@bicworld.comBethridge ToovellVP Global Communications+1 917 821 4249bethridge.toovell@bicworld.comIsabelle de SegonzacImage 7  Press Relations contact+33 6 89 87 61 39isegonzac@image7.frAgendaAll dates to be confirmedFull Year 2025 Results February 24  2026 First Quarter 2026 Net Sales April 28  2026 Annual General Meeting May 20  2026About BICA global leader in stationery  lighters  and shavers  BIC brings simplicity and joy to everyday life. For 80 years  BIC’s commitment to delivering high-quality  affordable  and trusted products has established BIC as a symbol of reliability and innovation. With a presence in over 160 countries  and over 13 000 team members worldwide  BIC’s portfolio includes iconic brands and products such as BIC® 4-Color™  BodyMark®  Cello®  Cristal®  Inkbox®  BIC Kids®  Lucky™  Rocketbook®  Tattly®  Tipp-Ex®  Wite-Out®  Djeep®  EZ Load™  EZ Reach®  BIC® Flex™  Soleil®  Tangle Teezer® and more. Listed on Euronext Paris and included in the SBF120 and CAC Mid 60 indexes  BIC is also recognized for its steadfast commitments to sustainability and education. For more  visit www.corporate.bic.com and to see BIC’s full range of products visit www.bic.com . Follow BIC on LinkedIn   Instagram   YouTube and TikTok .Attachment,neutral,0.0,1.0,0.0,positive,0.58,0.42,0.0,True,English,"['Own Shares', 'BIC', 'Disclosure', 'Trading', 'December', 'CAC Mid 60 indexes', 'Press Relations contact', 'VP Global Communications', 'Full Year 2025 Results', '2026 Annual General Meeting', 'VP Investor Relations', 'Société BIC', 'general regulation', 'global leader', 'full range', 'share buy-backs', 'Isabelle de', 'First Quarter', 'Net Sales', 'everyday life', '13,000 team members', 'iconic brands', 'EZ Load™', 'EZ Reach®', 'Tangle Teezer®', 'steadfast commitments', 'Euronext Paris', 'Own Shares', 'BIC® 4-Color™', 'BIC Kids®', 'BIC® Flex™', 'trusted products', 'Brice Paris', 'Bethridge Toovell', 'Disclosure', 'Trading', 'December', 'Clichy', 'France', 'January', 'compliance', 'transactions', 'Contacts', 'bicworld', 'Segonzac', 'Image', 'Agenda', 'dates', 'February', 'April', 'stationery', 'lighters', 'shavers', 'simplicity', 'joy', '80 years', 'symbol', 'reliability', 'innovation', 'presence', '160 countries', 'portfolio', 'BodyMark®', 'Cello®', 'Cristal®', 'Inkbox®', 'Lucky™', 'Rocketbook', 'Tattly®', 'Tipp-Ex®', 'Wite-Out®', 'Djeep', 'Soleil®', 'SBF120', 'sustainability', 'education', 'corporate', 'LinkedIn', 'Instagram', 'YouTube', 'TikTok', 'Attachment']",2026-01-06,2026-01-07,globenewswire.com
54566,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213310/0/en/Fagron-announces-the-completion-of-Purifarma.html,Fagron announces the completion of Purifarma,Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands)  6 January 2026 – 7:00 AM CET  Fagron announces the completion of...,Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands)  6 January 2026 – 7:00 AM CETFagron announces the completion of PurifarmaFagron  the leading global player in pharmaceutical compounding  is pleased to announce the completion of Purifarma in Brazil  an important milestone in executing our disciplined M&A strategy. The completion of this transaction follows competition clearance by CADE  the Brazilian antitrust authority  last October  and will strengthen Fagron’s scalable  high-quality platform  in line with the Group’s long-term growth objectives.Purifarma is a large-scale Essentials business with a competitive product portfolio and significant volumes. The company provides opportunities to improve mix  extend into industrial clients and capture operating leverage as volumes grow. The transaction is expected to deliver procurement benefits in Latin America and across the wider Group. The enterprise value of this acquisition is c.R$250 million.Rafael Padilla  CEO of Fagron  commented:“Completing Purifarma strengthens our position in Brazil and advances our disciplined buy-and-build strategy. Purifarma adds scale in Essentials with clear levers in mix  procurement and access to industrial clients. We will remain selective and execution-focused as we integrate these businesses and build a larger  more efficient platform.“Thank you to our teams worldwide for disciplined delivery. We have reinforced our positions in core markets  entered attractive new geographies and added capabilities that deepen our vertical integration  all aligned with our long-term ambition.”Financial calendar12 February 2026 Full year results 20259 April 2026 Trading update first quarter 202611 May 2026 Annual General Meeting 202530 July 2026 Half year results 20268 October 2026 Trading update third quarter 2026Results and trading updates are published at 7.00 AM CET.Further informationIgnacio ArtolaGlobal Investor Relations LeaderTel. +34 670385795ignacio.artola@fagron.comAbout FagronFagron is the leading global company active in pharmaceutical compounding  focusing on delivering personalized medicine to hospitals  pharmacies  clinics  and patients in more than 35 countries around the world.The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.Important information regarding forward-looking statementsCertain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently  Fagron cannot provide any guarantee that such forward-looking statements will  in fact  materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information  future events or for any other reason.In the event of differences between the English translation and the Dutch original of this press release  the latter prevails.Attachment,neutral,0.03,0.97,0.0,mixed,0.56,0.1,0.34,True,English,"['Fagron', 'completion', 'Purifarma', '11 May 2026 Annual General Meeting', 'Global Investor Relations Leader', 'disciplined M&A strategy', 'leading global player', 'Brazilian antitrust authority', 'competitive product portfolio', 'scalable, high-quality platform', 'long-term growth objectives', 'attractive new geographies', 'Full year results', 'Half year results', 'leading global company', 'large-scale Essentials business', 'Such forward-looking statements', '7:00 AM CET Fagron', 'build strategy', 'efficient platform', 'long-term ambition', 'new information', 'The Netherlands', 'pharmaceutical compounding', 'important milestone', 'competition clearance', 'industrial clients', 'operating leverage', 'Latin America', 'enterprise value', 'Rafael Padilla', 'clear levers', 'core markets', 'vertical integration', 'Financial calendar', 'Trading update', 'first quarter', 'third quarter', 'personalized medicine', 'Belgian company', 'Venecoweg 20A', 'Euronext Brussels', 'Euronext Amsterdam', 'ticker symbol', 'operational activities', 'Dutch company', 'head office', 'press release', 'current expectations', 'various risks', 'future events', 'other reason', 'English translation', 'Dutch original', 'Regulated information', 'Further information', 'Important information', 'significant volumes', 'procurement benefits', 'wider Group', 'Fagron NV', 'Fagron BV', 'Ignacio Artola', 'Purifarma Fagron', '7.00 AM', 'Nazareth', 'Belgium', 'Rotterdam', 'January', 'completion', 'transaction', 'CADE', 'opportunities', 'mix', 'acquisition', 'CEO', 'position', 'access', 'businesses', 'teams', 'delivery', 'capabilities', 'February', '9 April', 'July', 'October', 'Tel.', 'hospitals', 'pharmacies', 'clinics', 'patients', '35 countries', 'world', 'uncertainties', 'guarantee', 'fact', 'obligation', 'differences', 'latter', 'Attachment']",2026-01-06,2026-01-07,globenewswire.com
54567,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3214042/0/en/Half-year-review-of-Marie-Brizard-Wine-Spirits-liquidity-contract.html,Half-year review of Marie Brizard Wine & Spirits’ liquidity contract,Charenton-le-Pont  January 6  2026  Half-year review of Marie Brizard Wine & Spirits’ liquidity contract  Under Marie Brizard Wine & Spirits’...,Charenton-le-Pont  January 6  2026Half-year review of Marie Brizard Wine & Spirits’ liquidity contractUnder Marie Brizard Wine & Spirits’ liquidity contract with Natixis Oddo BHF  the liquidity account contained the following assets at 31 December 2025:95751 shares of Marie Brizard Wine & Spirits39097.19 Euros in cashFor reference  at the time the contract was established on 29 June 2018  the account held the following assets:75528 shares of Marie Brizard Wine & Spirits380177.12 Euros in cashOver the period from 1st July 2025 to 31 December 2025 the following operations were carried out:427 purchase transactions329 sale transactionsOver the same period  the volumes traded represented:78335 shares and 228687.75 Euros for purchase transactions75050 shares and 221350.93 Euros for sale transactionsInvestor Relations & ShareholdersGroupe MBWSEmilie Drexlerrelations.actionnaires@mbws.comTél : +33 1 43 91 62 40 MediaImage SeptClaire Doligez -Laurent Poinsotcdoligez@image7.fr -lpoinsot@image7.frTél : +33 1 53 70 74 70About Marie Brizard Wine & SpiritsMarie Brizard Wine & Spirits is a Group of wines and spirits based in Europe and the United States. Marie Brizard Wine & Spirits stands out for its expertise  a combination of brands with a long tradition and a resolutely innovative spirit. Since the birth of the Maison Marie Brizard in 1755  the Marie Brizard Wine & Spirits Group has developed its brands in a spirit of modernity while respecting its origins.Marie Brizard Wine & Spirits' commitment is to offer its customers brands of confidence  daring and full of flavours and experiences. The Group now has a rich portfolio of leading brands in their market segments  including William Peel  Sobieski  Marie Brizard and Cognac Gautier.Marie Brizard Wine & Spirits is listed on Compartment B of Euronext Paris (FR0000060873 - MBWS) and is part of the EnterNext PEA-PME150 index.Attachment,neutral,0.0,0.99,0.01,neutral,0.03,0.97,0.0,True,English,"['Marie Brizard Wine', 'Spirits’ liquidity contract', 'Half-year review', 'Natixis Oddo BHF', 'Laurent Poinsot cdoligez', 'Marie Brizard Wine', 'Maison Marie Brizard', 'Emilie Drexler relations', 'Spirits’ liquidity contract', 'Investor Relations', 'liquidity account', 'Half-year review', 'following assets', '1st July', 'following operations', '427 purchase transactions', '329 sale transactions', 'Tél', 'Claire Doligez', 'United States', 'long tradition', 'rich portfolio', 'market segments', 'William Peel', 'Cognac Gautier', 'Compartment B', 'Euronext Paris', 'EnterNext PEA-PME', 'The Group', ""Spirits' commitment"", 'same period', 'innovative spirit', 'Groupe MBWS', 'Image Sept', 'leading brands', 'Spirits Group', 'Charenton-le-Pont', 'January', '31 December', '95751 shares', '19 Euros', 'cash', 'reference', 'time', '29 June', '75528 shares', 'volumes', '78335 shares', '228687.75 Euros', '75050 shares', '221350.93 Euros', 'Shareholders', 'actionnaires', 'Media', 'lpoinsot', 'wines', 'Europe', 'expertise', 'combination', 'birth', 'modernity', 'origins', 'customers', 'confidence', 'flavours', 'experiences', 'Sobieski', '150 index', 'Attachment']",2026-01-06,2026-01-07,globenewswire.com
54568,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213931/0/en/Participation-notification-by-Morgan-Stanley.html,Participation notification by Morgan Stanley,Press release                                                                  Regulated information  Brussels  January 6  2026  17:45 CET   In line with...,Press release Regulated informationBrussels  January 6  2026  17:45 CETIn line with Belgian transparency legislation (Law of May 2  2007)  Morgan Stanley recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%.Here is a summary of the notificationVoting rights after the transaction Equivalent financial instruments after the transaction Total Previous 0.13% 3.17% 3.30% New 0.00% - 0.00%The notification  dated December 31  2025  contains the following information:Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities Downward crossing of the lowest thresholdNotified by: A parent undertaking or a controlling personDate on which the threshold is crossed: December 23  2025Threshold of direct voting rights crossed: 3% downwardsDenominator: 105 876 416Persons subject to the notification requirement: Morgan Stanley c/o The Corporation Trust Company (DE)  Corporation Trust Center  1209 Orange Street  Wilmington  Delaware 19801  USATransparency notifications and the full chain of controlled undertakings through which the holding is effectively held are available on the Investor Relations Section of Solvay's website.ContactsInvestor relationsGeoffroy d’Oultremont: +32 478 88 32 96Vincent Toussaint: +33 6 74 87 85 65Charlotte Vandevenne: +32 471 68 01 66investor.relations@solvay.comMedia relationsPeter Boelaert: +32 479 30 91 59Laetitia Van Minnenbruggen: +32 484 65 30 47media.relations@solvay.comAbout SolvaySolvay  a pioneering chemical company with a legacy rooted in founder Ernest Solvay's pivotal innovations in the soda ash process  is dedicated to delivering essential solutions globally through its workforce of circa 9 000 employees. Since 1863  Solvay has harnessed the power of chemistry to create innovative  sustainable solutions that answer the world’s most essential needs such as purifying the air we breathe and the water we drink  preserving our food supplies  protecting our health and well-being  creating eco-friendly clothing  making the tires of our cars more sustainable and cleaning and protecting our homes. Solvay’s unwavering commitment drives the transition to a carbon-neutral future by 2050  underscoring its dedication to sustainability and a fair and just transition. As a world-leading company with €4.7 billion in net sales in 2024  Solvay is listed on Euronext Brussels and Paris (SOLB). For more information about Solvay  please visit solvay.com or follow Solvay on Linkedin.Ce communiqué de presse est également disponible en français.Dit persbericht is ook in het Nederlands beschikbaar.Attachments,neutral,0.01,0.99,0.0,neutral,0.02,0.97,0.01,True,English,"['Participation notification', 'Morgan Stanley', 'Press release Regulated information', 'The Corporation Trust Company', 'Corporation Trust Center', 'Laetitia Van Minnenbruggen', 'pioneering chemical company', 'soda ash process', 'Belgian transparency legislation', 'innovative, sustainable solutions', 'Equivalent financial instruments', 'direct voting rights', 'founder Ernest Solvay', 'Investor Relations Section', 'following transparency notification', 'world-leading company', 'following information', 'Transparency notifications', 'essential solutions', 'voting securities', 'Morgan Stanley', 'parent undertaking', 'controlling person', '1209 Orange Street', 'full chain', 'controlled undertakings', 'Vincent Toussaint', 'Charlotte Vandevenne', 'Peter Boelaert', 'pivotal innovations', 'essential needs', 'food supplies', 'eco-friendly clothing', 'unwavering commitment', 'carbon-neutral future', 'net sales', 'français', 'Nederlands beschikbaar', 'Media relations', 'notification requirement', 'just transition', 'Euronext Brussels', 'communiqué de', 'lowest threshold', 'Solvay Solvay', 'January', 'CET', 'line', 'Law', 'May', 'summary', 'transaction', 'Reason', 'Acquisition', 'disposal', 'Date', 'December', 'Denominator', 'Persons', 'Wilmington', 'USA', 'holding', 'website', 'Contacts', 'Geoffroy', 'Oultremont', 'legacy', 'workforce', 'circa', '9,000 employees', 'power', 'chemistry', 'air', 'water', 'health', 'well-being', 'tires', 'cars', 'homes', 'dedication', 'sustainability', 'Paris', 'SOLB', 'Linkedin', 'presse', 'Dit', 'persbericht', 'het', 'Attachments', '32 479', '2050']",2026-01-06,2026-01-07,globenewswire.com
54569,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213311/0/en/Nexans-statement-on-the-Great-Sea-Interconnector-GSI-project.html,Nexans statement on the Great Sea Interconnector (GSI) project,Nexans statement on the Great Sea Interconnector (GSI) project  Paris  January 6th  2026 – Nexans wishes to provide additional clarifications regarding the...,Nexans statement on the Great Sea Interconnector (GSI) projectParis  January 6th  2026 – Nexans wishes to provide additional clarifications regarding the execution of the Great Sea Interconnector (GSI) contract.Nexans is executing the project in accordance with its contractual obligations  and in line with the milestones defined since 2023.A rescheduling of activities is ongoing with its customer. Nexans is therefore working closely with its customer to evaluate the best available options for a revised execution schedule.While these changes will affect the project delivery date  they will not affect Nexans’ 2028 financial guidance  thanks to the Group's large backlog and proactive actions to offset any potential impact starting in 2026.Nexans will provide its 2026 guidance alongside its full-year 2025 results on 19 February 2026.Nexans stays committed to executing this project with its customer.Beyond the GSI project  Nexans remains highly confident in the strong long-term growth prospects of the PWR-Transmission business  supported by structural trends and a robust and diversified order backlog.Julien Hueber  Chief Executive Officer of Nexans  said: “The GSI project remains underway and we are fully committed to supporting our customer in bringing this critical infrastructure to completion. We are managing this situation with strong discipline in our execution. The mitigating steps we are taking starting 2026 in response to external developments allow us to stay firmly on track with our financial trajectory as well as with our 2028 guidance. Supported by long-term structural demand and a solid backlog  Nexans’ PWR-Transmission business remains a strong driver of value creation  and we remain resolutely focused on disciplined execution.”About NexansNexans is the global pure player in sustainable electrification  building the essential systems that power the world’s transition to a connected  resilient  and low-carbon future. From offshore and onshore renewable energies to smart cities and homes  Nexans designs and delivers advanced cable solutions  accessories and services that electrify progress safely  efficiently  and sustainably.With over 140 years of history  through three core businesses: PWR Transmission  PWR Grid  and PWR Connect  Nexans blends deep industry expertise with cutting-edge innovation to accelerate the energy transition and better meet its customers' needs. Its unique E3 model  focused on Environment  Economy and Engagement  drives every action  aligning performance with purpose.Nexans operates in 41 countries with 28 500 people and generated €7.1 billion in standard sales in 2024. As recognized climate action leader  Nexans is committed to Net-Zero emissions by 2050 aligned with the Science Based Targets initiative (SBTi) and expanding energy access through the Fondation Nexans.Nexans is listed on Euronext Paris  Compartment A.www.nexans.com | #ElectrifyTheFutureContacts:Investor relationsAudrey BourgeoisTel. : +33 (0)1 78 15 00 43audrey.bourgeois@nexans.comCommunicationMael Evin (Havas Paris)Tel. : +33 (0)6 44 12 14 91nexans_h@havas.comMaellys Leosticmaellys.leostic@nexans.comOlivier Dabanolivier.daban@nexans.comAttachment,neutral,0.01,0.98,0.0,neutral,0.05,0.94,0.01,True,English,"['Great Sea Interconnector', 'Nexans statement', 'GSI) project', 'Science Based Targets initiative', 'strong long-term growth prospects', 'Great Sea Interconnector', 'best available options', 'Chief Executive Officer', 'long-term structural demand', 'global pure player', 'onshore renewable energies', 'advanced cable solutions', 'three core businesses', 'deep industry expertise', 'unique E3 model', 'Maellys Leostic maellys', 'diversified order backlog', 'climate action leader', 'Olivier Daban olivier', 'project delivery date', 'revised execution schedule', 'Nexans’ PWR-Transmission business', 'Nexans’ 2028 financial guidance', 'strong discipline', 'strong driver', 'structural trends', 'financial trajectory', 'large backlog', 'solid backlog', 'January 6th', 'additional clarifications', 'GSI) contract', 'contractual obligations', 'proactive actions', 'potential impact', 'full-year 2025 results', 'Julien Hueber', 'critical infrastructure', 'mitigating steps', 'external developments', 'value creation', 'sustainable electrification', 'essential systems', 'low-carbon future', 'smart cities', 'PWR Transmission', 'PWR Grid', 'PWR Connect', 'cutting-edge innovation', ""customers' needs"", 'standard sales', 'Net-Zero emissions', 'energy access', 'Compartment A.', 'ElectrifyTheFuture Contacts', 'Investor relations', 'Mael Evin', 'GSI) project', 'GSI project', 'disciplined execution', 'Euronext Paris', 'energy transition', 'Nexans statement', 'Fondation Nexans', 'Havas Paris', 'Audrey Bourgeois', '2026 guidance', '2028 guidance', 'accordance', 'milestones', 'rescheduling', 'activities', 'changes', 'Group', '19 February', 'robust', 'completion', 'situation', 'response', 'track', 'world', 'offshore', 'homes', 'accessories', 'services', 'progress', '140 years', 'history', 'Environment', 'Economy', 'Engagement', 'performance', 'purpose', '41 countries', '28,500 people', 'SBTi', 'Tel.', 'Communication', 'Attachment']",2026-01-06,2026-01-07,globenewswire.com
54570,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3214022/0/en/KBC-Group-KBC-Securities-and-Van-Lanschot-Kempen-Investment-Banking-announce-joint-venture-in-equities.html,KBC Group: KBC Securities and Van Lanschot Kempen Investment Banking announce joint venture in equities,KBC Securities and Van Lanschot Kempen Investment Banking announce joint venture in equities   Combination will be a leading equities broker in the Benelux...,KBC Securities and Van Lanschot Kempen Investment Banking announce joint venture in equitiesCombination will be a leading equities broker in the Benelux and pan-European specialist in real estate and life sciencesAttractive value proposition for clients based on expanded stock coverage  enhanced liquidity and increased placing power in core markets and sectorsJoint venture to operate under its own license and equal ownership of KBC Securities and Van Lanschot KempenJoint venture expected to start operations in Q4 2026  pending regulatory approvalBrussels  Amsterdam – KBC Securities and Van Lanschot Kempen Investment Banking announce their intention to combine their specialist equities activities into a 50/50 joint venture. The new entity will be a leading Benelux broker also specialising in pan-European real estate and life sciences. With this strong platform  clients will benefit from an expansion of stocks under research coverage and enhanced liquidity. The joint venture will support the investment banking activities of both KBC Securities and Van Lanschot Kempen Investment Banking  to deliver value to both corporate as well as institutional clients.Joint venture highlightsKBC Securities and Van Lanschot Kempen Investment Banking will transfer their equities businesses to the joint venture combining all current activities related to equity research  sales  sales-trading  trading and Equity Capital Markets (ECM) execution. Furthermore  the joint venture will be the exclusive distribution channel for all ECM business for the respective clients of Van Lanschot Kempen Investment Banking and KBC Securities. Both parties will continue to be engaged in client coverage in respect of ECM transactions and will independently offer corporate finance services  including M&A advice.Offering clients expanded coverage and liquidityFor investors  the joint venture will provide access to an extensive research coverage of about 230 stocks  with a strong focus on the Benelux region as well as European real estate and life sciences companies.For corporate clients  combining Van Lanschot Kempen’s pan-European  US and domestic investor base with KBC Securities’ Western-European and large domestic investor base is expected to substantially increase liquidity  placing power and investor coverage. The joint venture will deliver a broader client offering  combining expertise in corporate services such as liquidity providing and share buybacks with an extended geographic reach.The combination of complementary activities will establish a scalable platform with the potential to expand in the future.Johan Thijs  CEO of KBC Group  said: “This joint venture marks a pivotal step in the growth strategies of both Van Lanschot Kempen and KBC. By combining our local expertise with Van Lanschot Kempen’s complementary strengths  we are creating an international platform that gives access to European and US stock markets for Belgian corporate and institutional clients. This partnership reflects our commitment to long-term client success and innovation.”Maarten Edixhoven  Chair of the Management Board of Van Lanschot Kempen  said: “This is a perfect match considering the focus on client excellence we share  aligned values and complementary services. The joint venture will allow us to first of all serve our respective clients better  at scale. In addition  it will bolster the ongoing success of our corporate finance activities  a key part of our unique wealth management offering. We strongly believe in the value of long-term partnerships as a key element of scalable growth  and this is an excellent example.”Geert Cleuren  CEO of KBC Securities  said: “This partnership is entirely designed around client value. We will expand our reach and offer a full range of investment banking services  from equity research over trading to syndication. Together  we will create a Benelux powerhouse and become the reference for corporate and institutional clients.”Dirk Saltzherr  Co-Head of Van Lanschot Kempen Investment Banking  said:“We are delighted to work with KBC Securities to create a strong and future-proof equities platform that will enable our distinctive and specialist equities business to flourish. As equal partners we are committed to deliver even more value to our clients with a wider scope and reach. Moreover  we look forward to unlocking further growth potential to the benefit of our clients and other stakeholders.”Financial details and closing conditionsThe joint venture will lead to increased profitability of the activities in scope. The transaction is expected to have an impact of approximately a quarter of a percentage point on Van Lanschot Kempen’s capital ratio. The transaction will have no material impact on the CET1 ratio of KBC Group.The transaction is subject to customary closing conditions and is expected to close in Q4 2026. Until the closing  services to clients of KBC Securities and Van Lanschot Kempen will remain unchanged.About KBC SecuritiesKBC Securities is Belgium’s leading investment bank and part of the KBC Group. It provides financial services to a wide range of professional clients  including corporate and institutional clients  each with specific needs. KBC Securities offers solutions in corporate finance  equity and debt capital markets  mergers and acquisitions  private fundraising  and financial structuring. Institutional investors value its in-depth research and access to equity and bond transactions in the Benelux and beyond. It also provides investment services with access to a broad range of venture capital and private equity funds. With strong local roots and international expertise  KBC Securities supports companies across diverse sectors  including technology  life sciences  and real assets.More information is available at www.kbcsecurities.com.About Van Lanschot KempenVan Lanschot Kempen is an independent  specialist wealth manager active in private banking  investment management and investment banking  with the aim of preserving and creating wealth  in a sustainable way  for both its clients and the society of which it is part. Through our long-term focus  we create positive financial and non-financial value. Listed at Euronext Amsterdam  Van Lanschot Kempen is the Netherlands’ oldest independent financial services company  with a history dating back to 1737.For more information  please visit vanlanschotkempen.com* This news item contains information that is subject to the transparency regulations for listed companies.Attachment,neutral,0.0,1.0,0.0,positive,0.75,0.24,0.0,True,English,"['Van Lanschot Kempen Investment Banking', 'KBC Group', 'KBC Securities', 'joint venture', 'equities', 'Van Lanschot Kempen Investment Banking', 'Van Lanschot Kempen Joint venture', 'unique wealth management offering', 'large domestic investor base', 'investment banking activities', 'investment banking services', 'leading investment bank', 'exclusive distribution channel', 'M&A advice', 'broader client offering', 'leading equities broker', 'leading Benelux broker', 'sectors Joint venture', '50/50 joint venture', 'Joint venture highlights', 'future-proof equities platform', 'specialist equities business', 'life sciences companies', 'extended geographic reach', 'specialist equities activities', 'pan-European real estate', 'US stock markets', 'Attractive value proposition', 'Equity Capital Markets', 'customary closing conditions', 'extensive research coverage', 'long-term client success', 'corporate finance activities', 'corporate finance services', 'KBC Securities’ Western-European', 'investor coverage', 'pan-European specialist', 'Management Board', 'pan-European, US', 'stock coverage', 'core markets', 'equities businesses', 'equity research', 'client coverage', 'ECM business', 'ongoing success', 'long-term partnerships', 'capital ratio', 'client excellence', 'current activities', 'complementary activities', 'scalable platform', 'international platform', 'corporate services', 'complementary services', 'equities Combination', 'expanded coverage', 'equal ownership', 'regulatory approval', 'new entity', 'ECM) execution', 'ECM transactions', 'Benelux region', 'share buybacks', 'Johan Thijs', 'KBC Group', 'pivotal step', 'growth strategies', 'complementary strengths', 'Belgian corporate', 'Maarten Edixhoven', 'perfect match', 'key element', 'scalable growth', 'excellent example', 'Geert Cleuren', 'client value', 'full range', 'Benelux powerhouse', 'Dirk Saltzherr', 'equal partners', 'other stakeholders', 'Financial details', 'percentage point', 'CET1 ratio', 'strong platform', 'institutional clients', 'respective clients', 'corporate clients', 'local expertise', 'key part', 'wider scope', 'growth potential', 'material impact', 'strong focus', 'KBC.', 'liquidity', 'placing', 'license', 'operations', 'Q4', 'Brussels', 'Amsterdam', 'intention', 'expansion', 'stocks', 'sales', 'trading', 'parties', 'investors', 'access', 'CEO', 'commitment', 'innovation', 'Chair', 'values', 'scale', 'addition', 'syndication', 'reference', 'Head', 'distinctive', 'benefit', 'profitability', 'quarter', 'Belgium']",2026-01-06,2026-01-07,globenewswire.com
54571,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213321/0/en/Progress-on-share-buyback-programme.html,Progress on share buyback programme,Progress on share buyback programme  ING announced today that  as part of our €1.1 billion share buyback programme announced on 30 October 2025  in total...,Progress on share buyback programmeING announced today that  as part of our €1.1 billion share buyback programme announced on 30 October 2025  in total 1 390 645 shares were repurchased during the week of 29 December up to and including 2 January 2026.The shares were repurchased at an average price of €24.00 for a total amount of €33 375 275.28. For detailed information on the daily repurchased shares  individual share purchase transactions and weekly reports  see the updates on the share buyback programme on our website.In line with the purpose of the programme to reduce the share capital of ING  the total number of shares repurchased under this programme to date is 17 721 238 at an average price of €22.63 for a total consideration of €401 080 731.57. To date approximately 36.46% of the maximum total value of the share buyback programme has been completed.Note for editorsFor further information on ING  please visit www.ing.com. Frequent news updates can be found in the Newsroom. Photos of ING operations  buildings and its executives are available for download at Flickr.Press enquiries Investor enquiries ING Group Media Relations ING Group Investor Relations +31 20 576 5000 +31 20 576 6396 media.relations@ing.com Investor.Relations@ing.comING PROFILEING is a global financial institution with a strong European base  offering banking services through its operating company ING Bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank’s more than 60 000 employees offer retail and wholesale banking services to customers in over 100 countries.ING Group shares are listed on the exchanges of Amsterdam (INGA NA  INGA.AS)  Brussels and on the New York Stock Exchange (ADRs: ING US  ING.N).ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers  which give updates on them annually. ING's ESG rating by MSCI has been upgraded from 'AA' to 'AAA' in October 2025. As of June 2025  in Sustainalytics’ view  ING’s management of ESG material risk is ‘Strong’ with an ESG risk rating of 18.0 (low risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext  STOXX  Morningstar and FTSE Russell. Society is transitioning to a low-carbon economy. So are our clients  and so is ING. We finance a lot of sustainable activities  but we still finance more that’s not. Follow our progress on ing.com/climate.IMPORTANT LEGAL INFORMATIONElements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‘Market Abuse Regulation’).ING Group’s annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‘IFRS- EU’). In preparing the financial information in this document  except as described otherwise  the same accounting principles are applied as in the 2024 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.Certain of the statements contained herein are not historical facts  including  without limitation  certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to diﬀer materially from those expressed or implied in such statements. Actual results  performance or events may diﬀer materially from those in such statements due to a number of factors  including  without limitation: (1) changes in general economic conditions and customer behaviour  in particular economic conditions in ING’s core markets  including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets  including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‘benchmark’ indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally  including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non- compliance with or changes in laws and regulations  including those concerning financial services  financial economic crimes and tax laws  and the interpretation and application thereof (11) geopolitical risks  political instabilities and policies and actions of governmental and regulatory authorities  including in connection with the invasion of Russia into Ukraine and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations  including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING’s ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes  including write down and conversion powers in relation to our securities (17) outcome of current and future litigation  enforcement proceedings  investigations or other regulatory actions  including claims by customers or stakeholders who feel misled or treated unfairly  and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws  including FATCA (19) operational and IT risks  such as system disruptions or failures  breaches of security  cyber-attacks  human error  changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete  inaccurate  or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the eﬀects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy  including such risks and challenges as a consequence of the use of emerging technologies  such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors  including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business  operational  regulatory  reputation  transition and other risks and challenges in connection with climate change  diversity  equity and inclusion and other ESG-related matters  including data gathering and reporting and also including managing the conflicting laws and requirements of governments  regulators and authorities with respect to these topics (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks  including in connection with use of models  use of derivatives  or maintaining appropriate policies and guidelines (29) changes in capital and credit markets  including interbank funding  as well as customer deposits  which provide the liquidity and capital required to fund our operations  and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures  including press releases  which are available on www.ING.com.This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information  internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy  completeness  reasonableness or reliability of such information. This document may also discuss one or more specific transactions and/or contain general statements about ING’s ESG approach. The approach and criteria referred to in this document are intended to be applied in accordance with applicable law. Due to the fact that there may be different or even conflicting laws  the approach  criteria or the application thereof  could be different.Materiality  as used in the context of ESG  is distinct from  and should not be confused with  such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‘SEC’) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes. In addition  there is currently no single  globally recognized set of accepted definitions in assessing whether activities are “green” or “sustainable.” Without limiting any of the statements contained herein  we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security  use of proceeds  a description of applicable project(s) and/or any other relevant information  please reference the offering documents for such security.This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only  and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of  or take any responsibility for  any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document  or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.Any forward-looking statements made by or on behalf of ING speak only as of the date they are made  and ING assumes no obligation to publicly update or revise any forward-looking statements  whether as a result of new information or for any other reason.This document does not constitute an oﬀer to sell  or a solicitation of an oﬀer to purchase  any securities in the United States or any other jurisdiction.Attachment,neutral,0.41,0.58,0.01,mixed,0.11,0.13,0.75,True,English,"['share buyback programme', 'Progress', '2024 ING Group consolidated annual accounts', 'New York Stock Exchange', 'individual share purchase transactions', 'ING Groep N.V.', 'International Financial Reporting Standards', 'ING Group Media Relations', 'operating company ING Bank', 'ING Bank N.V.', '€1.1 billion share buyback programme', 'ING Group Investor Relations', 'currency exchange rates', 'international response measures', 'same accounting principles', 'global economic impact', 'interest rate levels', 'state compensation schemes', 'ESG index products', 'related international response', 'global financial institution', 'financial economic crimes', 'strong European base', 'Market Abuse Regulation', 'major market participant', 'ESG material risk', 'general economic conditions', 'particular economic conditions', 'related market disruption', 'daily repurchased shares', 'maximum total value', 'ESG risk rating', 'wholesale banking services', 'IMPORTANT LEGAL INFORMATION', 'ING Group shares', 'Frequent news updates', 'other forward-looking statements', 'ESG rating', 'share capital', 'Investor enquiries', 'financial services', 'low risk', 'financial markets', 'EU Regulation', 'European Union', 'financial information', 'ING operations', 'ING PROFILE', 'average price', 'total amount', 'weekly reports', 'total consideration', 'Press enquiries', 'INGA NA', 'INGA.AS', 'independent research', 'ratings providers', 'Sustainalytics’ view', 'major sustainability', 'leading providers', 'FTSE Russell', 'low-carbon economy', 'sustainable activities', 'press release', 'IFRS- EU', 'Small differences', 'historical facts', 'future expectations', 'current views', 'unknown risks', 'actual results', 'customer behaviour', 'core markets', 'developing markets', 'fiscal uncertainty', 'United States', 'principal markets', 'capital markets', 'counterparty creditworthiness', 'geopolitical risks', 'political instabilities', 'regulatory authorities', 'detailed information', 'total number', 'tax laws', '1,390,645 shares', 'Progress', '30 October', '29 December', '2 January', 'website', 'line', 'purpose', 'Note', 'editors', 'Newsroom', 'Photos', 'buildings', 'executives', 'download', 'Flickr', 'people', 'life', 'business', '60,000 employees', 'retail', 'customers', '100 countries', 'exchanges', 'Amsterdam', 'Brussels', 'ADRs', 'heart', 'policies', 'MSCI', 'AA', 'June', 'management', 'examples', 'Euronext', 'STOXX', 'Morningstar', 'Society', 'clients', 'lot', 'Elements', 'meaning', 'Article', 'accordance', 'document', 'figures', 'tables', 'rounding', 'limitation', 'assumptions', 'uncertainties', 'performance', 'events', 'factors', 'regional', 'invasion', 'Russia', 'Ukraine', 'default', 'discontinuation', 'benchmark', 'indices', 'inflation', 'deflation', 'borrower', 'failures', 'banks', 'scope', 'compliance', 'regulations', 'interpretation', 'application', 'governmental', 'connection', '18.0']",2026-01-06,2026-01-07,globenewswire.com
54572,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2026/01/06/3213935/0/en/KL%C3%89PIERRE-SEMI-ANNUAL-STATEMENT-OF-LIQUIDITY-AGREEMENT.html,KLÉPIERRE: SEMI-ANNUAL STATEMENT OF LIQUIDITY AGREEMENT,REGULATED RELEASE  SEMI-ANNUAL STATEMENTOF LIQUIDITY AGREEMENT  Paris – January 6  2026  In accordance with the provisions of the French Financial Markets...,REGULATED RELEASESEMI-ANNUAL STATEMENTOF LIQUIDITY AGREEMENTParis – January 6  2026In accordance with the provisions of the French Financial Markets Authority’s decision no. 2021-01 of June 22  2021  establishing liquidity contracts as an accepted market practice  Klépierre informs the public of the implementation of the liquidity contract for the second half of 2025:Available resources on December 31  2025: 54 727 Klépierre shares and 11 047 453.80 euros;Number of transactions on buy side over second half of 2025: 3 086;Number of transactions on sell side over second half of 2025: 3 680;Traded volume on buy side over second half of 2025: 2 642 317 shares for 87 804 551.88 euros;Traded volume on sell side over second half of 2025: 2 677 415 shares for 89 112 220.33 euros.As a reminder At June 30  2025  available resources were 89 825 Klépierre shares and 9 639 816.34 euros.At the date of signature of the liquidity contract with Kepler Cheuvreux  February 1  2023  the available resources were 0 Klépierre share and 10 738 920.93 euros.TRANSACTIONS DETAILSDate Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01/07/2025 37 35 44 000 40 000 1 464 760.00 1 332 800.00 02/07/2025 33 29 40 000 20 000 1 328 000.00 666 400.00 03/07/2025 40 50 30 000 42 000 1 001 100.00 1 403 640.00 04/07/2025 53 49 40 000 35 045 1 330 800.00 1 168 049.85 07/07/2025 4 68 4 000 33 663 134 080.00 1 131 413.43 08/07/2025 39 3 38 000 721 1 233 100.00 23 490.18 09/07/2025 12 45 12 000 36 350 387 360.00 1 179 557.50 10/07/2025 36 53 32 000 40 000 1 039 680.00 1 302 800.00 11/07/2025 17 8 24 000 8 210 775 920.00 266 004.00 14/07/2025 46 34 20 448 30 289 664 560.00 988 330.07 15/07/2025 35 12 38 000 12 100 1 247 160.00 401 720.00 16/07/2025 38 20 27 552 22 000 893 786.88 715 220.00 17/07/2025 60 46 38 000 32 000 1 233 860.00 1 041 600.00 18/07/2025 13 29 14 000 30 000 455 140.00 978 900.00 21/07/2025 7 41 9 000 31 672 295 020.00 1 039 158.32 22/07/2025 3 57 6 000 36 456 196 680.00 1 200 860.64 23/07/2025 16 32 22 000 21 999 727 100.00 729 266.85 24/07/2025 29 49 34 000 36 532 1 128 120.00 1 215 784.96 25/07/2025 39 33 28 630 16 000 950 516.00 533 440.00 28/07/2025 40 41 22 000 28 000 733 260.00 933 800.00 29/07/2025 35 29 30 000 27 470 999 900.00 916 124.50 30/07/2025 7 31 6 297 31 010 210 823.56 1 039 455.20 31/07/2025 73 50 96 000 76 172 3 213 120.00 2 554 047.16 July 2025 712 844 655 927 687 689 21 643 846.44 22 761 862.66 01/08/2025 29 36 42 000 39 828 1 404 060.00 1 333 043.16 04/08/2025 - 31 - 24 000 - 817 200.00 05/08/2025 21 45 26 000 28 000 898 560.00 968 240.00 06/08/2025 5 32 10 000 20 570 348 300.00 717 893.00 07/08/2025 47 7 24 000 8 121 836 880.00 284 478.63 08/08/2025 6 21 6 000 21 879 209 340.00 764 889.84 11/08/2025 20 26 18 000 10 500 628 560.00 366 765.00 12/08/2025 34 28 33 000 17 000 1 150 710.00 595 680.00 13/08/2025 - 47 - 21 227 - 741 459.11 14/08/2025 27 16 30 000 3 773 1 045 800.00 132 809.60 15/08/2025 7 47 6 000 20 000 207 720.00 694 000.00 18/08/2025 51 32 22 000 14 000 765 820.00 488 460.00 19/08/2025 17 32 14 000 14 000 489 300.00 490 000.00 20/08/2025 - 29 - 17 000 - 598 570.00 21/08/2025 21 3 10 604 4 628 373 578.92 163 183.28 22/08/2025 15 33 4 000 16 000 141 080.00 565 760.00 25/08/2025 49 1 41 000 1 1 439 100.00 35.40 26/08/2025 67 5 40 000 1 035 1 366 800.00 35 397.00 27/08/2025 36 28 34 000 14 000 1 147 160.00 474 180.00 28/08/2025 26 8 26 000 8 000 864 500.00 266 560.00 29/08/2025 27 40 8 000 32 000 265 840.00 1 066 880.00 August 2025 505 547 394 604 335 562 13 583 108.92 11 565 484.02Date Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01/09/2025 21 16 20 000 11 001 664 800.00 366 443.31 02/09/2025 41 - 40 000 - 1 315 200.00 - 03/09/2025 25 29 26 000 14 000 849 420.00 459 060.00 04/09/2025 2 50 2 000 48 000 65 280.00 1 583 520.00 05/09/2025 9 34 14 000 34 512 462 420.00 1 148 904.48 08/09/2025 23 36 28 000 18 116 936 040.00 607 429.48 09/09/2025 45 10 30 000 9 310 1 001 100.00 312 536.70 10/09/2025 41 28 29 000 14 000 963 380.00 467 460.00 11/09/2025 18 27 18 074 20 183 601 141.24 673 304.88 12/09/2025 2 49 4 000 32 000 133 320.00 1 074 880.00 15/09/2025 23 18 28 000 12 000 937 440.00 403 680.00 16/09/2025 40 - 30 000 - 991 800.00 - 17/09/2025 28 14 12 000 13 000 392 280.00 426 660.00 18/09/2025 37 45 31 000 30 200 1 017 420.00 995 090.00 19/09/2025 37 77 12 083 47 000 395 234.93 1 545 360.00 22/09/2025 28 11 16 200 10 000 532 656.00 330 000.00 23/09/2025 35 20 26 073 16 016 857 280.24 528 367.84 24/09/2025 13 27 12 000 20 160 392 880.00 661 449.60 25/09/2025 22 39 10 410 30 000 340 302.90 986 100.00 26/09/2025 7 42 8 000 26 000 263 120.00 858 260.00 29/09/2025 28 35 22 001 24 000 725 372.97 792 240.00 30/09/2025 38 29 21 999 24 000 723 767.10 791 520.00 September 2025 563 636 440 840 453 498 14 561 655.38 15 012 266.29 01/10/2025 18 30 26 000 20 157 855 660.00 664 173.15 02/10/2025 9 18 12 000 20 100 393 000.00 660 888.00 03/10/2025 25 19 32 000 8 192 1 043 840.00 269 680.64 06/10/2025 48 1 46 000 2 000 1 473 380.00 64 880.00 07/10/2025 36 - 30 000 - 949 200.00 - 08/10/2025 6 40 6 000 30 000 189 300.00 950 400.00 09/10/2025 9 47 2 000 44 000 63 360.00 1 406 240.00 10/10/2025 33 8 20 000 12 000 640 800.00 386 160.00 13/10/2025 68 24 30 000 24 000 958 800.00 771 840.00 14/10/2025 15 50 12 000 48 000 391 080.00 1 580 160.00 15/10/2025 19 31 20 000 32 000 653 200.00 1 051 520.00 16/10/2025 9 59 16 000 34 000 525 120.00 1 122 340.00 17/10/2025 33 11 24 834 10 000 815 300.22 329 000.00 20/10/2025 26 23 28 000 14 000 914 480.00 460 040.00 21/10/2025 - 101 - 32 000 - 1 053 120.00 22/10/2025 - 46 - 25 026 - 832 865.28 23/10/2025 22 23 27 000 18 000 905 310.00 606 240.00 24/10/2025 16 137 18 526 24 000 616 360.02 803 280.00 27/10/2025 29 - 24 000 - 799 440.00 - 28/10/2025 17 27 12 000 19 414 398 040.00 646 097.92 29/10/2025 24 13 15 658 12 000 521 098.24 400 800.00 30/10/2025 42 25 27 376 28 000 907 788.16 929 320.00 31/10/2025 29 8 14 000 12 000 464 800.00 398 520.00 October 2025 533 741 443 394 468 889 14 479 356.64 15 387 564.99Date Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 03/11/2025 12 8 8 000 14 000 264 720.00 464 380.00 04/11/2025 26 22 12 000 32 000 395 760.00 1 062 720.00 05/11/2025 21 15 18 000 12 000 595 440.00 398 280.00 06/11/2025 12 41 14 000 30 000 464 660.00 999 600.00 07/11/2025 9 40 12 000 22 000 399 120.00 735 460.00 10/11/2025 1 13 2 000 14 000 67 000.00 471 240.00 11/11/2025 - 25 - 12 000 - 408 000.00 12/11/2025 27 31 22 000 10 000 750 860.00 342 500.00 13/11/2025 25 12 14 000 6 000 478 660.00 205 500.00 14/11/2025 37 - 24 000 - 815 280.00 - 17/11/2025 27 15 21 117 14 000 711 854.07 472 500.00 18/11/2025 31 4 18 000 4 092 598 500.00 136 590.96 19/11/2025 21 17 18 000 14 077 597 600.00 468 623.33 20/11/2025 13 21 14 001 6 055 463 853.13 202 055.35 21/11/2025 27 21 34 000 24 000 1 114 860.00 790 080.00 24/11/2025 49 31 42 000 39 952 1 371 720.00 1 307 229.44 25/11/2025 22 49 38 000 44 048 1 250 580.00 1 450 941.12 26/11/2025 9 36 12 000 22 000 397 080.00 732 380.00 27/11/2025 9 20 11 001 16 000 369 303.57 538 080.00 28/11/2025 4 13 6 208 10 000 208 340.48 336 300.00 November 2025 382 434 340 327 346 224 11 315 191.25 11 522 460.20 01/12/2025 21 10 14 000 12 000 468 860.00 402 960.00 02/12/2025 21 9 20 000 8 000 670 800.00 269 360.00 03/12/2025 30 22 26 000 22 000 868 920.00 738 540.00 04/12/2025 20 3 26 000 2 000 863 720.00 66 800.00 05/12/2025 13 9 20 000 10 000 659 800.00 331 200.00 08/12/2025 24 19 22 000 26 000 725 780.00 858 520.00 09/12/2025 32 26 30 000 30 224 990 600.00 998 600.96 10/12/2025 25 4 18 000 6 000 592 200.00 198 060.00 11/12/2025 14 23 14 000 30 000 457 100.00 983 400.00 12/12/2025 10 22 6 225 19 838 203 993.25 654 654.00 15/12/2025 16 35 26 000 25 438 861 640.00 845 050.36 16/12/2025 18 37 20 000 38 000 661 400.00 1 261 980.00 17/12/2025 18 36 30 000 24 000 1 000 200.00 801 840.00 18/12/2025 - 45 - 34 000 - 1 143 080.00 19/12/2025 31 82 36 000 20 000 1 208 160.00 672 800.00 22/12/2025 27 35 15 000 28 000 502 800.00 942 200.00 23/12/2025 13 16 18 000 14 000 608 580.00 474 600.00 24/12/2025 35 6 10 000 5 667 337 400.00 191 487.93 29/12/2025 12 23 8 000 20 333 269 280.00 687 255.40 30/12/2025 - 16 - 10 053 - 340 193.52 31/12/2025 11 - 8 000 - 270 160.00 - December 2025 391 478 367 225 385 553 12 221 393.25 12 862 582.17 SECOND HALF 2025 3 086 3 680 2 642 317 2 677 415 87 804 551.88 89 112 220.33AGENDAFebruary 19  2026May 7  2026May 7  2026 2025 full-year earnings (after market close)First quarter 2026 trading update (before market opening)Annual General MeetingINVESTOR RELATIONS CONTACTS Laurent Budd  CFA Group Head of IR and Financial Communication+33 (0)6 86 59 74 36 — laurent.buddt@klepierre.comHugo Martins  IR Manager+33 (0)7 72 11 63 24 — hugo.martins@klepierre.comTanguy Phelippeau  IR Manager+33 (0)7 72 09 29 57 — tanguy.phelippeau@klepierre.comABOUT KLÉPIERREKlépierre is the European leader in shopping malls  with an exclusive focus on continental Europe. The Company’s portfolio is valued at €20.6 billion at June 30  2025  and comprises large shopping centers in more than 10 countries in continental Europe which together host more than 700 million visitors per year. Klépierre is a French REIT (SIIC) listed on Euronext Paris and is included in the CAC Next 20 and EPRA Euro Zone Indexes. It is also included in ethical indexes  such as CAC SBT 1.5  MSCI Europe ESG Leaders  FTSE4Good  Euronext Vigeo Europe 120  and features in CDP’s “A list”. These distinctions underscore the Group’s commitment to a proactive sustainable development policy and its global leadership in the fight against climate change..For more information  please visit the newsroom on our website: www.klepierre.comAttachment,neutral,0.01,0.99,0.01,neutral,0.02,0.97,0.01,True,English,"['KLÉPIERRE', 'SEMI-ANNUAL STATEMENT', 'LIQUIDITY AGREEMENT', 'French Financial Markets Authority', '0 Klépierre share', 'Buy side Number', 'Sell side Number', '54,727 Klépierre shares', '89,825 Klépierre shares', 'TRANSACTIONS DETAILS Date', 'REGULATED RELEASE', 'SEMI-ANNUAL STATEMENT', 'LIQUIDITY AGREEMENT', 'liquidity contracts', 'market practice', 'second half', 'Kepler Cheuvreux', 'EUR Sell', 'available resources', '2,642,317 shares', '77,415 shares', 'Paris', 'January', 'accordance', 'provisions', 'decision', 'June', 'accepted', 'public', 'implementation', 'December', 'volume', 'reminder', 'signature', 'February', '10,738,920.93 euros', 'September', '453.80', '87', '88', '33', '6.34']",2026-01-06,2026-01-07,globenewswire.com
